Citations

Clear

10 citation(s) found for "Sun, Michael".

Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
Thomas, Charlene , Nauseef, Jones T. , Sun, Michael Philip, Castellanos, Sandra Huicochea , Beltran, Himisha , Molina, Ana M. , Davidson, Zachary, Patel, Amie , Nanus, David M. , Vallabhajosula, Shankar , Bander, Neil H. , Tagawa, Scott T. , Sartor, Oliver , Ricaurte‐Fajardo, Andres , Demichelis, Francesca , Sigouros, Michael , Orlando, Francesco , Lewis, Brian E. , Osborne, Joseph R.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 5074-5074

10.1200/jco.2024.42.16_suppl.5074 Get It

5074 Background: PC commonly expresses PSMA and has dose-responsive radiosensitivity. 177Lu-based radioligands usually use an empiric dosing regimen. This 1st dose-escalation study of 177Lu-PSMA-617 employed a dose-dense fractionation schedule intended to allow delivery of higher total doses to overcome radioresistance due to repopulation. Here, we report mature results of the study. Methods: Progressive mCRPC following > 1 potent ARPI (e.g., abi/enza) and chemo (or unfit/refuse taxane) without limit of # prior therapies provided adequate organ function and ECOG PS 0-2. Treatment: single cycle of fractionated dose 177Lu-PSMA-617 on D1 and D15. In Ph I dose-escalation, patients (pts) received one cycle of 7.4 - 22 GBq followed by Simon 2-stage Ph II at 22.2 GBq. PSMA expression was not required for treatment, but pre- and post-treatment 68Ga-PSMA11 PET/CT and/or 177Lu-PSMA-617 SPECT done. Primary efficacy by PSA changes with 2ndary outcomes with CT/bone scans, PSMA PET, circulating tumor cell (CTC; CellSearch) counts, plasma DNA (PCF_SELECT), and survival. Results: Between 1/2017 – 2/2021, 50 pts treated with median PSA 164.3, 35 (70%) CALGB (Halabi) poor risk. 47 (94%) bone, 38 (76%) nodal, 12 (24%) lung, 5 (10%) liver mets (4 additional pts with PSMA PET+ liver mets not apparent on CT). 29 (58%) with prior >2 ARPI, 29 (58%) with >1 chemo, 14 (28%) with Ra-223, 2 (4%) with 177Lu-J591. 27 (54%) treated at 22 GBq. No dose-limiting toxicity during Ph I. 38 (76%) with any PSA decline, 27 (54%) with >50% PSA. Median rPFS 8.3 mo [5.6-16.7], and OS 15.7 mo [10.9-20.6]. Of 17 RECIST measurable, 6 (35.3%) responded, 7 (41.2%) stable, 4 (23.5%) progressed. Of 31 with paired CTC counts, 16 (52%) decreased, 5 (16%) were stable; 10 (32.3%) converted to favorable/undetectable. Plasma DNA with high allele-specific ploidy and ARcopy number gain associated with OS (univariate). Treatment emergent adverse events (TEAE): 32 (64%) dry mouth, 22 (44%) pain flare, 22 (44%) fatigue, 19 (38%) nausea, 15 (30%) anemia, 15 (28%) thrombocytopenia (plts), 9 (18%) neutropenia (ANC). All TEAEs restricted to grade (Gr) 1-2 except 6 (12%) with Gr 3 anemia, 2 (4%) Gr 3/4 plts, 1 (2%) Gr 3 ANC. TEAE incidence and Gr were not related to dose. On multivariable analysis, 177Lu dose administered (p=0.09), CALGB risk (p=0.04), prior chemo (p=0.009), associated with OS; dose (p=0.1), CALGB risk (p=0.2), and AR copy number (p=0.2) associated with PSA50 decline. Baseline PSMA imaging (by imaging score or SUVmax) was not associated with OS or response. Conclusions: A single-cycle of fractionated-dose 177Lu-PSMA-617 is safe. Despite no pre-selection for PSMA expression, most had PSA decline with favorable PFS and OS compared to historical controls and similar to PSMA-selected targeted radionuclide studies administering multiple cycles in a less dose-intense approach. Clinical trial information: NCT03042468 .
Abstract CT225: Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial
Nauseef, Jones T. , Thomas, Charlene , Sun, Michael, Jacobs, Nicole , Rüder, S, Fernandez, Escarleth, Davidson, Zachary, Patel, Amie , Vallabhajosula, Shankar , Molina, Ana M. , Nanus, David M. , Castellanos, Sandra Huicochea , Bander, Neil H. , Jacobs, Nicole, Ricaurte‐Fajardo, Andres , Sartor, Oliver , Sternberg, Cora N , Osborne, Joseph R. , Perk, Timothy , Tagawa, Scott T.

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: CT225-CT225

10.1158/1538-7445.am2024-ct225 Get It

Abstract Background: We have previously reported that 177Lu-PSMA-617 given as a single-cycle, dose-intense regimen for patients (pts) with pretreated mCRPC is efficacious even without selection by PSMA (ESMO 2021). Quantitative analyses of pre-treatment PSMA PET may allow for better patient selection and prediction of toxicities. Analyses of sequential PET images may also provide insights that may be associated with longer term outcomes. Our previous analysis of 13 patients demonstrated association of PSMA PET signal with overall survival (OS) and PSA responses, as well as trends with adverse events (Nauseef GU ASCO 2022). Here we present long-term follow up data and expanded imaging correlatives from our completed phase I/II study. MethodsEntry criteria: progressive mCRPC after at least one prior potent AR pathway inhibitor and prior chemotherapy (excepting men ineligible for or refusing of chemotherapy) with allowance for prior radionuclides (incl. Ra223 and PSMA-TRTs). Treatment was fractionated-dose (D1 and D15) 177Lu-PSMA-617 (7.4-22.2 GBq). TRAQinform IQ (AIQ Solutions) was used to identify, track, and quantify regions of interest suspicious of cancer (lesion-ROI) on PSMA PET/CT images and quantify uptake in normal organs outside of lesion-ROI. Measurements included SUVmean across all lesion-ROI, volume of lesion-ROI, and SUVtotal (sum of SUV in all lesion-ROI), as well as changes after treatment, including in PSMA-expressing healthy tissues. Associations with survival were tested via Cox proportional hazard models in univariate analyses and associations with adverse events (AEs) and PSA responses were via assessed via Wilcoxon rank sum tests. Results32 pts (of 50 total in the study between 1/2017-2/2021) had pre- and post-treatment imaging suitable TRAQinform IQ analysis and associated survival analyses. Baseline characteristics were similar to the entire study cohort. PSA response of 50% was observed in 21/32 (66%) of which 16 were confirmed. No imaging variable predicted PSA30 or PSA50, although an association was observed in pretreatment SUVmean and lesion-ROI volume reduction. No imaging variable was significantly associated with OS (e.g., pretx SUVmean HR 0.9, p=0.10, pretx Volume HR 1.00, p=0.052). Pretx SUVmean was associated with mPFS (HR 0.85, 95% CI 0.74, 0.98, p=0.023). Among select AEs, anemia was associated with non-lesion-ROI skeleton SUVtotal in pre- (p=0.027) and post-tx (p=0.007). Higher pre-treatment salivary gland uptake (SUVmean) was associated with more xerostomia (p=0.11). Fatigue was associated with a variety of variables including salivary SUVs (mean, max, and total) and post-tx bowel SUVmax (p=0.030). ConclusionsPre-treatment and pre- to post-treatment 68Ga-PSMA11-PET data analyzed may be associated with outcome. While a strength of this study is the prospective nature of patient enrollment and fixed imaging timepoints, our associations are limited by small sample size. Expansion of this analysis to larger datasets may improve our ability to predict treatment response and toxicity by body-wide PSMA detection. Citation Format: Jones Trevor Nauseef, Charlene Thomas, Michael Sun, Nicole Jacobs, Andrés Ricaurte Fajardo, Sam Ruder, Escarleth Fernandez, Zachary Davidson, Amie Patel, A. Oliver Sartor, Shankar Vallabhajosula, Ana Molina, Cora N. Sternberg, David M. Nanus, Sandra Huicochea Castellanos, Joseph Osborne, Neil H. Bander, Timothy Perk, Scott Tagawa. Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT225.
Longitudinal Quantitative EEG Changes Correlate With Neuropsychological Assessment Decline (P4.041)
Caviness, John N., Hentz, Joe, Driver‐Dunckley, Erika, Belden, Christine M. , Powell, Jessica, Driver‐Dunckley, Erika , Ahmadi, Michael , Adler, Charles H.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.p4.041 Get It

Cerebral white matter rarefaction has both neurodegenerative and vascular causes and may primarily be a distal axonopathy
Beach, Thomas G. , Sue, Lucia I., Scott, Sarah, Intorcia, Anthony J., Walker, Jessica E. , Arce, Richard, Glass, Michael J. , Borja, Claryssa I., Cline, Madison P. , Hemmingsen, Spencer J, Qiji, Sanaria H., Stewart, Analisa M. , Martinez, Kayleigh N, Krupp, Addison, McHattie, Rylee, Mariner, Monica, Lorenzini, Ileana , Kuramoto, Angela, Long, Kathy E., Tremblay, Cécilia , Caselli, Richard J. , Woodruff, Bryan K. , Rapscak, Steven Z., Belden, Christine M. , Goldfarb, Danielle, Driver‐Dunckley, Erika , Mehta, Shyamal H. , Shill, Holly A. , Driver-Dunckley, Erika D., Adler, C H , Choudhury, Parichita , Sabbagh, Marwan Noel , Atri, Alireza , Adler, Charles H. , Serrano, Geidy E.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | April 18, 2023 | Volume: 82 | Issue: 6 | Pages: 457-466

10.1093/jnen/nlad026 | PMID 37071794 Get It

Abstract Cerebral white matter rarefaction (CWMR) was considered by Binswanger and Alzheimer to be due to cerebral arteriolosclerosis. Renewed attention came with CT and MR brain imaging, and neuropathological studies finding a high rate of CWMR in Alzheimer disease (AD). The relative contributions of cerebrovascular disease and AD to CWMR are still uncertain. In 1181 autopsies by the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), large-format brain sections were used to grade CWMR and determine its vascular and neurodegenerative correlates. Almost all neurodegenerative diseases had more severe CWMR than the normal control group. Multivariable logistic regression models indicated that Braak neurofibrillary stage was the strongest predictor of CWMR, with additional independently significant predictors including age, cortical and diencephalic lacunar and microinfarcts, body mass index, and female sex. It appears that while AD and cerebrovascular pathology may be additive in causing CWMR, both may be solely capable of this. The typical periventricular pattern suggests that CWMR is primarily a distal axonopathy caused by dysfunction of the cell bodies of long-association corticocortical projection neurons. A consequence of these findings is that CWMR should not be viewed simply as “small vessel disease” or as a pathognomonic indicator of vascular cognitive impairment or vascular dementia.
SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19
Serrano, Geidy E. , Walker, Jessica E. , Tremblay, Cécilia , Huentelman, Matthew J. , Belden, Christine M. , Goldfarb, Danielle, Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caselli, Richard J. , Woodruff, Bryan K. , Haarer, Chadwick F., Ruhlen, Thomas, Nguyen, Steve, Schmitt, Dasan, Rapscak, Steven Z., Bime, Christian , Peters, Joseph L., Alevritis, Ellie, Arce, Richard, Glass, Michael J. , Vargas, Daisy, Sue, Lucia I., Intorcia, Anthony J., Nelson, Courtney M. , Oliver, Javon, Russell, Aryck, Suszczewicz, Katsuko E., Borja, Claryssa I., Cline, Madison P. , Hemmingsen, Spencer J, Qiji, Sanaria H., Hobgood, Holly M, Zhang, Haiyu , Solis, Daniel , Montine, Thomas J. , Berry, Gerald J. , Reiman, Eric M. , Röltgen, Katharina , Boyd, Scott D. , Zehnder, James L. , Desforges, Marc , DeTure, Michael , Beach, Thomas G. , Driver-Dunckley, Erika, Berry, Gerald J , Serrano, Geidy E , Piras, Ignazio Stefano , Shprecher, David , Atri, Alireza , Adler, Charles H. , Haarer, Chadwick F., Torres, Marı́a José , Peters, Joseph L, Mizgerd, Joseph P. , Sahoo, Malaya Kumar , Pinsky, Benjamin A. , Talbot, Pierre J. , Dickson, Dennis W.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | July 12, 2022 | Volume: 81 | Issue: 9 | Pages: 666-695

10.1093/jnen/nlac056 | PMID 35818336 Get It

Abstract Brains of 42 COVID-19 decedents and 107 non-COVID-19 controls were studied. RT-PCR screening of 16 regions from 20 COVID-19 autopsies found SARS-CoV-2 E gene viral sequences in 7 regions (2.5% of 320 samples), concentrated in 4/20 subjects (20%). Additional screening of olfactory bulb (OB), amygdala (AMY) and entorhinal area for E, N1, N2, RNA-dependent RNA polymerase, and S gene sequences detected one or more of these in OB in 8/21 subjects (38%). It is uncertain whether these RNA sequences represent viable virus. Significant histopathology was limited to 2/42 cases (4.8%), one with a large acute cerebral infarct and one with hemorrhagic encephalitis. Case-control RNAseq in OB and AMY found more than 5000 and 700 differentially expressed genes, respectively, unrelated to RT-PCR results; these involved immune response, neuronal constituents, and olfactory/taste receptor genes. Olfactory marker protein-1 reduction indicated COVID-19-related loss of OB olfactory mucosa afferents. Iba-1-immunoreactive microglia had reduced area fractions in cerebellar cortex and AMY, and cytokine arrays showed generalized downregulation in AMY and upregulation in blood serum in COVID-19 cases. Although OB is a major brain portal for SARS-CoV-2, COVID-19 brain changes are more likely due to blood-borne immune mediators and trans-synaptic gene expression changes arising from OB deafferentation.
Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis
Beach, Thomas G. , Sue, Lucia I., Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Intorcia, Anthony J., Glass, Michael J. , Walker, Jessica E. , Arce, Richard, Nelson, Courtney M. , Driver-Dunckley, Erika, Adler, Charles H. , Serrano, Geidy E.

Mayo Clinic

Journal of Parkinson's Disease | June 15, 2021 | Volume: 11 | Issue: 4 | Pages: 1833-1843

10.3233/jpd-212733 | PMID 34151862 Get It

Background: Braak and others have proposed that Lewy-type α-synucleinopathy in Parkinson’s disease (PD) may arise from an exogenous pathogen that passes across the gastric mucosa and then is retrogradely transported up the vagus nerve to the medulla. Objective: We tested this hypothesis by immunohistochemically staining, with a method specific for p-serine 129 α-synuclein (pSyn), stomach and vagus nerve tissue from an autopsy series of 111 normal elderly subjects, 33 with incidental Lewy body disease (ILBD) and 53 with PD. Methods: Vagus nerve samples were taken adjacent to the carotid artery in the neck. Stomach samples were taken from the gastric body, midway along the greater curvature. Formalin-fixed paraffin-embedded sections were immunohistochemically stained for pSyn, shown to be highly specific and sensitive for α-synuclein pathology. Results: Median disease duration for the PD group was 13 years. In the vagus nerve none of the 111 normal subjects had pSyn in the vagus, while 12/26 ILBD (46%) and 32/36 PD (89%) subjects were pSyn-positive. In the stomach none of the 102 normal subjects had pSyn while 5/30 (17%) ILBD and 42/52 (81%) of PD subjects were pSyn-positive. Conclusion: As there was no pSyn in the vagus nerve or stomach of subjects without brain pSyn, these results support initiation of pSyn in the brain. The presence of pSyn in the vagus nerve and stomach of a subset of ILBD cases indicates that synucleinopathy within the peripheral nervous system may occur, within a subset of individuals, at preclinical stages of Lewy body disease.
Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease
Callan, Michael, Cutler, Brett, Glass, Michael J. , Walker, Jessica E. , Intorcia, Anthony J., Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Belden, Christine M. , Zamrini, Edward , Sue, Lucia I., Vargas, Daisy, Beach, Thomas G. , Driver-Dunckley, Erika, Serrano, Geidy E. , Shprecher, David , Zhang, Nan , Adler, Charles H.

Mayo Clinic

Brain Communications | January 28, 2020 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaa004 | PMID 32064463 Get It

Abstract Comorbid Lewy body pathology is very common in Alzheimer’s disease and may confound clinical trial design, yet there is no in vivo test to identify patients with this. Tissue (and/or radioligand imaging) studies have shown cardiac sympathetic denervation in Parkinson’s disease and dementia with Lewy bodies, but this has not been explored in Alzheimer’s subjects with Lewy bodies not meeting dementia with Lewy bodies clinicopathological criteria. To determine if Alzheimer’s disease with Lewy bodies subjects show sympathetic cardiac denervation, we analysed epicardial and myocardial tissue from autopsy-confirmed cases using tyrosine hydroxylase and neurofilament immunostaining. Comparison of tyrosine hydroxylase fibre density in 19 subjects with Alzheimer’s disease/dementia with Lewy bodies, 20 Alzheimer’s disease with Lewy bodies, 12 Alzheimer’s disease subjects without Lewy body disease, 19 Parkinson’s disease, 30 incidental Lewy body disease and 22 cognitively normal without Alzheimer’s disease or Lewy body disease indicated a significant group difference (P < 0.01; Kruskal–Wallis analysis of variance) and subsequent pair-wise Mann–Whitney U tests showed that Parkinson’s disease (P < 0.05) and Alzheimer’s disease/dementia with Lewy bodies (P < 0.01) subjects, but not Alzheimer’s disease with Lewy bodies subjects, had significantly reduced tyrosine hydroxylase fibre density as compared with cognitively normal. Both Parkinson’s disease and Alzheimer’s disease/dementia with Lewy bodies subjects also showed significant epicardial losses of neurofilament protein-immunoreactive nerve fibre densities within the fibre bundles as compared with cognitively normal subjects (P < 0.01) and both groups showed high pathologic alpha-synuclein densities (P < 0.0001). Cardiac alpha-synuclein densities correlated significantly with brain alpha-synuclein (P < 0.001), while cardiac tyrosine hydroxylase and neurofilament immunoreactive nerve fibre densities were negatively correlated with the densities of both brain and cardiac alpha-synuclein, as well as Unified Parkinson’s Disease Rating Scale scores (P < 0.05). The clear separation of Alzheimer’s disease/dementia with Lewy bodies subjects from Alzheimer’s disease and cognitively normal, based on cardiac tyrosine hydroxylase fibre density, is the first report of a statistically significant difference between these groups. Our data do not show significant sympathetic cardiac denervation in Alzheimer’s disease with Lewy bodies, but strongly confirm that cardiac nuclear imaging with a noradrenergic radioligand is worthy of further study as a potential means to separate Alzheimer’s disease from Alzheimer’s disease/dementia with Lewy bodies during life.
A phase 1 safety study of SBP-101, a polyamine metabolic inhibitor, for pancreatic ductal adenocarcinoma (PDA).
Kotasek, Dusan , Borazanci, Erkut , Smith, Sheri , Shah, Ajit , Walker, Michael J. , Cullen, Michael, Gagnon, Suzanne , Borazanci, Erkut , Tebbutt, Niall C. , Borad, Mitesh J. , Cullen, Michael T.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e16231-e16231

10.1200/jco.2018.36.15_suppl.e16231 Get It